Pipeline

Status of pipelines

Leading pipelines

  • Pipelines
  • Target Type
  • Modality
  • Indication
  • Development stage

  • ADEL-Y01

  • Target Type

    Tau
    (acetylated lysine 280, acK280)

  • Modality

    monoclonal antibody (humanized)

  • Indication

    Alzheimer's disease
    or Tauopathy
    (rare disease)

  • Development stage

    Clinical, phase 1
    (USA FDA)

  • ADEL-Y03

  • Target Type

    MHC-I - free (unbound)
    β2-microglobulin (β2m)

  • Modality

    monoclonal antibody

  • Indication

    Alzheimer's Disease, Aging, Fibrosis (Kidney, Liver, Lung), Cancer, Inflammation

  • Development stage

    Preclinical efficacy

  • ADEL-Y04

  • Target Type

    ApoE4

  • Modality

    monoclonal antibody

  • Indication

    Alzheimer's Disease and Metabolic disease

  • Development stage

    Preclinical efficacy

  • ADEL-Y07

  • Target Type

    Androgen Receptor
    Tau aggregates

  • Modality

    small molecule

  • Indication

    Prostate cancer,
    Alzheimer’s Disease

  • Development stage

    Discovery

  • ADEL-D01

  • Target Type

    phosphorylated Tau (T217)

  • Modality

    monoclonal antibody

  • Indication

    Alzheimer's Disease, Dementia, Tauopathy

  • Development stage

    Diagnostic product development in progress